ISHLInternational Symposium on Hodgkin LymphomaProgram at a Glance
Saturday (22.10.2022)
Sunday (23.10.2022)
Monday (24.10.2022)
Großer Saal
Interactive Case Discussion
T. Illidge
J. Zijlstra
Case presentation: Greyzone Lymphoma
L. Pinczés
Case presentation: Anti-PD1 Failure
G. Collins
Case presentation: COVID19 immunity in lymphoma
S. Mellinghoff
Case presentation: Primary progressive HL
A. Jacob
Großer Saal
Advanced Stages
O. Casasnovas
J. Radford
Why I recommend BV-AVD
R. Advani
Why I recommend PET-guided ABVD
A. Fosså
Why I recommend PET-adapted escalated BEACOPP
P. Borchmann
Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective
M. Dreyling
J. Richardson
S. Wells
WS Report: Learning through International Collaboration
P. Borchmann
A. Moskowitz
FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
W. Plattel
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
P. Borchmann
Seminars and
Workshops(parallel sessions)
Seminar:
Living beyond Lymphoma
L. Specht
F. van Leeuwen
Workshop:
The HL Microenvironment
S. Rodig
A. Rosenwald
Workshop:
PET beyond Deauville
S. Barrington
M. Hutchings
C. Kobe
Workshop:
Innovation for Older Patients
P. Bröckelmann
A. Fosså
Joint EHA-ISHL Symposium
P. Borchmann
M. Dreyling
Coffee Break
Coffee Break
Großer Saal
Emerging Cellular Therapies – a Role in HL?
S. Ansell
P. Borchmann
Clinical experience with Cellular Therapy in cH
B. Savoldo
Design and manufacturing of CD30 CARs for cHL
C. Quintarelli
Emerging indications for cellular therapy
P. Borchmann
Großer Saal
Special Situations in HL
R. Hoppe
M. Kersten
HL in Pregnancy
D. Dierickx
HIV-positive HL
O. Baiocchi
alloSCT in the era of anti-PD1
A. Sureda
Coffee Break
Coffee Break
Coffee Break
Seminars and
Workshops(parallel sessions)
Seminar:
Radiotherapy: Identifying the Beneficiaries
C. Baues
J. Yahalom
Workshop:
Bringing Liquid Biopsy to Patients
S. Borchmann
D. Rossi
Seminar:
Learning from Pediatric HL
J. Friedberg
C. Mauz-Körholz
Workshop:
NLPHL
M. Binkley
D. Eichenauer
S. Hartmann
Großer Saal
Living beyond Lymphoma
J. Radford
F. van Leeuwen
Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors
K. Linton
GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study
K. Behringer
WS Report: Living beyond Lymphoma
L. Specht
F. van Leeuwen
Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
S. Neppelenbroek
Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
J. Entrop
Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
M. Dinan
Großer Saal
Genomics, Biology and Microenvironment
W. Klapper
R. Küppers
Biological Classification of HL by Liquid Biopsy
S. Borchmann
Single Cell Transcriptomics of HL
C. Steidl
WS Report: Bringing Liquid Biopsy to Patients
S. Borchmann
D. Rossi
Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
K. Karihtala
High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
A. Diepstra
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
J. Paczkowska
Coffee Break
Coffee Break
Coffee Break
Großer Saal
Opening paths to the next chapters of lymphoma treatmen
by Beigene
In memoriam of Saul Rosenberg
R. Advani
Welcome and Introduction to the topic
P. Borchmann
Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma
P. Bröckelmann
The challenge of the older patient in lymphoma therapy
G. Collins
New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies
P. Zinzani
Großer Saal
Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma
by Takeda
G. Collins
A. Herrera
P. Zinzani
Welcome and introduction
G. Collins
Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1
G. Collins
Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)
G. Collins
A. Herrera
P. Zinzani
Audience Q&A
Summary and close
G. Collins
Großer Saal
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives
by MSD
P. Borchmann
Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?
P. Borchmann
The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma
B. von Tresckow
Strategies to enhance checkpoint inhibition
P. Bröckelmann
Coffee Break
Coffee Break
Coffee Break
Großer Saal
Early Stages
M. André
H. Eich
Standard treatment of early-stage HL
J. Radford
Individual risk assessment of RT in HL
R. Hoppe
WS Report: NLPHL
M. Binkley
D. Eichenauer
S. Hartmann
Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
D. Eichenauer
Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
A. Gallamini
Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
R. Shakir
Großer Saal
Older and Frail Patients
R. Cordoba Mascuñano
A. Evens
Managing an Older Lymphoma Patient
R. Cordoba Mascuñano
Treatment Strategies in Older HL Patients
A. Evens
Workshop Report: Innovation for Older patients
P. Bröckelmann
A. Fosså
AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
N. Övergaard
The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
J. Upshaw
Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
I. Buvat
Großer Saal
Relapsed / Refractory HL
R. Advani
C. Moskowitz
1ˢᵗ Relapse of HL
C. Moskowitz
Novel developments in R/R HL
G. Collins
WS Report: PET beyond Deauville
S. Barrington
M. Hutchings
C. Kobe
Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
A. Sureda
High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
A. Moskowitz
Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
C. Diefenbach
Coffee Break
Coffee Break
Großer Saal
Closing Remarks
Conference Highlights
R. Advani
Großer Saal
CAR T cell therapy in B Cell NHL: Status quo and future perspectives
by Bristol-Myers Squibb
P. Borchmann
P. Cramer
Status quo of CAR T cell therapy for r/r DLBCL
P. Borchmann
New perspective for the treatment of r/r CLL
P. Cramer
CAR T – Lessons Learned
C. Scheid
Großer Saal
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma
by Takeda
A. Sureda
Welcome and introduction
A. Sureda
Navigating Complex Treatment Decisions in R/R HL
T. Vasilakopoulos
Challenging Case Study #1
M. Hutchings
Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL
A. Sureda
Challenging Case Study #2
M. Hutchings
Audience Q&A
Foyer (First Floor)
Farewell
Coffee Break
Coffee Break
Großer Saal
Opening and Award Ceremony
Welcoming Address
A. Engert
Award Ceremony
P. Borchmann
S. Borchmann
P. Bröckelmann
D. Eichenauer
Introduction to the Keynote Lecturer
V. Diehl
Keynote Lecture
U. Şahin
Großer Saal
Immunotherapy
P. Armand
P. Zinzani
New findings and new challenges since last ISHL
S. Ansell
Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
R. Lynch
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
J. Timmerman
Vision Corner Stimulus Talk: The future of translational science in HL
C. Steidl
Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment
G. Collins
Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure